Eric Topol

Tell us a little bit about your migration.

Well, we're fortunate for that.

And also with your work with CGI to help propel that forward and

I think it sounds like we're going to need a lot of help to get this thing done.

Now, Charlotte, as a computer scientist now at EPFL, what are you going to do to keep working on this?

And what's your career advice for people in computer science who have an interest in digital biology?

Well, you know, Cheryl, the way you're set up there,

with this coalescence of life science and computer science is so ideal and so unusual here in the US.

That's fantastic.

That's what we need and that's really the underpinning of how you're going to get to the virtual cells, getting these two communities together.

Steve, likewise, you were an engineer and somehow you became one of the pioneers of digital biology way back before you had that term.

This interdisciplinary, transdisciplinary, we need so much of that in order for you all to be successful, right?

Now, a couple of people who you know well have made some pretty big statements about this whole era of digital biology.

And I think, you know, the virtual cell is perhaps the biggest initiative of all the digital biology ongoing efforts.

But Jensen Wong wrote, the first time in human history, biology has the opportunity to be engineering, not science.

And Demis Hassabis wrote,

said we're seeing engineering science you have to build the artifact of interest first then use the scientific method to reduce it down and understand its components well here there's a lot to do to understand its components and if we can do that like for example right now as both of you know AI drug discoveries and high gear and there's umpteen numbers of companies working on it but it doesn't account for the sell

I mean, it basically is protein, protein ligand interactions.

What if we had drug discovery that was cell based?

Could you comment about that?